ASSOCIATION OF COVID-19 VACCINATION WITH FEMALE OVARIAN RESERVE

To evaluate the association of COVID-19 vaccination with female ovarian reserve. A retrospective cohort study of women from January 2018 to October 2021 who presented as new patients to a reproductive endocrinology and infertility clinic in Houston, Texas was conducted. Inclusion criteria were documentation of vaccination in the electronic health record, presence of anti-Mullerian hormone (AMH) laboratory value, presence of ovarian antral follicle count by ultrasound. Exclusion criteria were incomplete data and no documentation of vaccination. Demographics including age, diagnosis, date of visit, zipcode, laboratory values were also obtained. Primary outcome was ovarian reserve as defined by the value of anti-Mullerian hormone and antral follicle count on ultrasound. Chi-square and one-way ANOVA were used to calculate differences in baseline characteristics. Odds ratios were calculated for each predictor variable using logistic regression. Of the 1654 patients evaluated, 944 (57%) had documentation of vaccination, 771 (82%) met inclusion criteria. Of those, 678 patients were in the pre vaccination cohort and 92 post vaccination. There were no differences in baseline characteristics of age, diagnoses, median household income, BMI, HbA1c, or TSH values. There was no change in AMH (OR 0.41 95% CI 0.14-1.14) and no difference in antral follicle count (OR 1.01 95% CI 0.99-1.03) after vaccination. The mean AMH in the cohort prior to vaccination was 4.2 and post was 5.2. The mean follicle count pre and post were 20.9 and 22.5, respectively. There was no significant differences in ovarian reserve in our patient population before and after receiving COVID-19 vaccination. Limitations include sample size number and local variations in laboratory values.